摘要
目的 探讨miR-409-3p和Rab10对弥漫大B细胞淋巴瘤(DLBCL)的影响。方法 qRT-PCR检测转染miR-409-3p模拟物(miR-409-3p mimic)、无关序列模拟物(mimic NC)、miR-409-3p抑制物(miR-409-3p inhibitor)、无关序列抑制物(inhibitor NC)和空白对照组(control组)后miR-409-3p的表达水平,使用Targetscan 7.2和miRNA靶基因预测数据库(miRDB)预测miR-409-3p的下游靶基因,Western blot检测Rab GTP酶10(Rab10)的表达,细胞计数试剂盒-8(CCK-8)和流式细胞仪用来检测细胞增殖和凋亡,然后使用免疫组化(IHC)检测石蜡包埋组织中Rab10的表达水平并进一步分析Rab10与DLBCL患者临床特征的关系。结果 miR-409-3p可以促进细胞凋亡,抑制细胞增殖;过表达miR-409-3p后Rab10的表达增加;Rab10在DLBCL组织中的表达水平高于淋巴结反应性增生(RHL)组织,高水平乳酸脱氢酶(LDH)、高水平β2微球蛋白(β2-MG)和淋巴瘤国际预后评分(IPI)高的患者Rab10的表达相对较高。结论 miR-409-3p可以促进细胞凋亡及Rab10的表达,Rab10与患者的不良预后有关。
Objective To investigate the effects of Rab10 and miR-409-3p in diffuse large B-cell lymphoma(DLBCL).Methods qRT-PCR was used to determine miR-409-3p levels following transfection with miR-409-3p mimic,mimic NC,miR-409-3p inhibitor,inhibitor NC and blank control group(control group).Targetscan 7.2 and miRNA target prediction Database(miRDB)software were used to predict the target gene of miR-409-3p.Western blot assay was performed to investigate the expression levels of Rab GTPase10(Rab10).Cell counting Kit-8(CCK-8)and flow cytometry assays were performed to determine the levels of cell viability and apoptosis.Finally,the expression of Rab10 in paraffin-embedded tissues was detected by immunohistochemical(IHC)method,and then the relationship between Rab10 and clinical characteristics in patients with DLBCL was compared.Results miR-409-3p could promote the apoptosis and inhibit proliferation of tumor cells.Overexpression of miR-409-3p increased the Rab10 mRNA and protein levels in DLBCL cells.The expression of Rab10 in DLBCL was higher than that in reactive hyperplasia of lymph nodes,and the level of it was positively correlated with lactate dehydrogenase(LDH),β2-microglobulin(β2-MG)and international prognostic score for lymphoma(IPI)of DLBCL patients.Conclusion miR-409-3p can promote the apoptosis of tumor cells and the expression of Rab10,Rab10 is associated with the adverse prognosis in DLBCL.
作者
蔡青照
艾丽梅
Cai Qingzhao;Ai Limei(Dept of Hematology, First Affiliated Hospital of Jinzhou Medical University,Jinzhou 121001)
出处
《安徽医科大学学报》
CAS
北大核心
2022年第6期914-919,共6页
Acta Universitatis Medicinalis Anhui
基金
辽宁省自然科学基金(编号:20180550001)。